Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Myelodysplastic syndrome+3

Not recruiting

Registered drugNo placebo

Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Codeine Phosphate

Contact Research Centre

Myelodysplastic syndrome

Not recruiting

Registered drug

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Myelodysplastic syndrome

Not recruiting

Registered drugNo placebo

Study of ALX148 and Azacitidine for Untreated Higher Risk Myelodysplastic Syndrome Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Alx148

Contact Research Centre

Myelodysplastic syndrome+1

Not recruiting

InvestigationalNo placebo

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Contact Research Centre

Myelodysplastic syndrome+1

Not recruiting

Registered drugNo placebo

Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Canakinumab

Contact Research Centre

Myelodysplastic syndrome

Not recruiting

Registered drugNo placebo

Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa

Contact Research Centre

Myelodysplastic syndrome+1

Not recruiting

Registered drugNo placebo

Study of MP0533 for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Using Sodium Dihydrogen Phosphate Dihydrate, Polysorbate 20, and Sodium Chloride

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Myelodysplastic syndrome

Not recruiting

Registered drug

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Myelodysplastic syndrome+1

Not recruiting

InvestigationalNo placebo

Study of AG-946 for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Ag-946

Contact Research Centre

Myelodysplastic syndrome+1

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Treatment Failure

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Hydrocortisone

Contact Research Centre

Myelodysplastic syndrome

Not recruiting

Registered drugNo placebo

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa

Contact Research Centre

Myelodysplastic syndrome+1

Not recruiting

Registered drugNo placebo

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Decitabine

Contact Research Centre

Find therapies in clinical trials near you – page 4

53 trials match your criteria

Myelodysplastic syndrome+3

Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

Myelodysplastic syndrome

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic syndrome

Study of ALX148 and Azacitidine for Untreated Higher Risk Myelodysplastic Syndrome Patients

Myelodysplastic syndrome+1

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic syndrome+1

Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

Myelodysplastic syndrome

Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

Myelodysplastic syndrome+1

Study of MP0533 for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Using Sodium Dihydrogen Phosphate Dihydrate, Polysorbate 20, and Sodium Chloride

Myelodysplastic syndrome

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Myelodysplastic syndrome+1

Study of AG-946 for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes

Myelodysplastic syndrome+1

Study on the Effectiveness of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Treatment Failure

Myelodysplastic syndrome

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Myelodysplastic syndrome+1

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.